Navigation Links
Positive Results of InspireMD's MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
Date:11/5/2012

uperior performance relative to standard stents in STEMI patients, the MGuard EPS requires no change in current physician practice - an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the OTC under the ticker symbol NSPR.

About MGuard™ Embolic Protection Coronary Stent

MGuard™ EPS combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that is integrated with the stent. The MGuard EPS is designed to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard EPS is CE Mark approved. MGuard™ is not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) n
'/>"/>

SOURCE InspireMD, Inc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
3. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
9. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
10. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... National Institute of,Standards and Technology (NIST) has selected ... Commerce Department,s Advanced Technology Program,(ATP), a peer-reviewed competition. ... the early-phase Michigan biotechnology company developing,drug therapies to ... disorders. Velcura scientists have discovered a family ...
... YORK, Sept. 27 Immtech Pharmaceuticals,Inc. (Immtech) (Amex: ... Food and Drug,Administration of the People,s Republic of ... for conducting a Phase III clinical,trial with pafuramidine, ... Pneumocystis pneumonia (PCP). Pafuramidine is among the first,drugs ...
Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Chinese SFDA Grants Immtech Fast Track Status 2Chinese SFDA Grants Immtech Fast Track Status 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving ... according to new research from The University of ... National guidelines state that health care professionals (HCPs) ... a healthy weight. Firefighters have high rates of ... of line-of-duty deaths in firefighters. This study assessed ...
(Date:7/11/2014)... The Corn Farming industry ... on the heels of fresh biofuel demand. The Federal ... a larger share of their farmland to cultivating high-value ... required the mixing of 5.0% renewable content in gasoline ... United States created a key export market for Canadian ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
(Date:7/11/2014)... Riverside Health System became the first provider ... in late 2012 and now, in partnership with Williamsburg Landing, ... the Williamsburg and Newport News region. , Also known as ... to independent older adults who wish to remain in their ... of continuing care services as well as control over the ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... not quintessentially masculine, women in their fertile phase are ... women paired with George Clooney types. But women ... to their partners, a recent study co-authored by a ... a man,s intelligence has no effect on the extent ...
... Residents of Cuyahoga County, and later Lorain County, will ... of a national resource for childhood growth and development. ... of children,s health ever conducted in the United States. ... The study will enroll women who are pregnant ...
... -- People over age 65 are at increased risk for ... study finds. Latent tuberculosis occurs when TB bacteria lurk ... has no symptoms of TB and is not contagious. However, ... cause tuberculosis, which can be fatal if it goes untreated. ...
... has received a boost from a surprising source: the 2009 ... 2009 H1N1 strain developed antibodies that are protective against a ... Medicine and the University of Chicago have found. The results ... Medicine . "Our data shows that infection with the ...
... one of today,s most exciting scientific and clinical areas. ... rulings by regulatory bodies or ethical controversies. These often ... ethicists, legislators, the media and the public. ESHRE,s ... of the world,s leading experts in reproductive medicine gather ...
... Race and ethnicity play major roles in whether people get ... much less likely to undergo colonoscopies than white people. Now, ... people live. Research by oncologist Dr. Thomas Semrad ... Center found that location makes a big difference in rates ...
Cached Medicine News:Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Case Western Reserve University School of Medicine launches the National Children's Study 2Health News:Treating Latent TB After 65 Raises Serious Side-Effect Risk 2Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: